A cohort study on the risk of major adverse kidney events for new patients initiated on empagliflozin versus other non-SGLT2I antihyperglycemics.
Read More »The Effect of Dapagliflozin on Renal Disease Progression
There is a potential role in using dapagliflozin in patients with CKD.
Read More »Optimal Treatment In T2D For CV Protection
How triple therapy can lead to optimal cardiovascular and renal protection.
Read More »The Benefits of Exenatide From the EXSCEL Study
The EXSCEL trial may not have shown that once-weekly exenatide had cardiovascular benefits for patients with diabetes, but did show a benefit in some significant areas.
Read More »Sotagliflozin: Implications in Patients Living With Chronic Kidney Disease
A new phase 3 study on novel SGLT inhibitor shows favorable results in those living with severe renal impairment.
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »SGLT-2 Inhibitors and the Risk for Urosepsis
Are SGLT-2 inhibitors responsible for urosepsis or Fournier's gangrene?
Read More »SGLT2 Inhibitors for Kidney Disease
A 56-year old male with type 2 diabetes and stage 3 chronic kidney disease contacted us recently regarding his new prescription for the SGLT2 inhibitor canagliflozin (Invokana)....
Read More »Diabetes Prevention: The Key To Reducing End-stage Kidney Disease
Earlier onset of type 2 diabetes equals higher risk of kidney transplant.
Read More »Risks Associated with Age of Diabetes Onset
Compelling evidence suggests that the age of diabetes diagnosis may be linked to the risk of end-stage kidney disease.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.